450960
Lutetium(III) chloride
anhydrous, powder, 99.99% trace metals basis
Synonym(s):
Lutetium chloride, Lutetium trichloride
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
LuCl3
CAS Number:
Molecular Weight:
281.33
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12352302
EC Number:
233-240-1
MDL number:
Assay:
99.99% trace metals basis
Grade:
anhydrous
Form:
powder
grade
anhydrous
assay
99.99% trace metals basis
form
powder
reaction suitability
core: lutetium, reagent type: catalyst
impurities
≤150.0 ppm Trace Rare Earth Analysis
mp
905 °C (lit.)
density
3.98 g/mL at 25 °C (lit.)
SMILES string
Cl[Lu](Cl)Cl
InChI
1S/3ClH.Lu/h3*1H;/q;;;+3/p-3
InChI key
AEDROEGYZIARPU-UHFFFAOYSA-K
Application
Lutetium(III) chloride can be used:
- As a precursor to synthesize chiral bridged lutetium catalyst for asymmetric hydroamination.
- As a starting material to prepare doped lutetium oxide nanophosphors.
- To fabricate scintillation detectors such as lutetium aluminum garnet (LuAG).
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Rare earth elements are vital in everyday life worldwide: catalysts in cars, colors in screens, magnets in electronics. Essential for modern living.
Development of new technologies for the manufacturing of nanocrystalline scintillation materials
Nikoloz V Jalabadze, et al.
IEEE transactions on nuclear science, 55, 1514-1522 (2008)
A Chiral-Bridged Aminotroponiminate Complex of Lutetium as Catalyst for the Asymmetric Hydroamination
Nils Meyer, et al.
Organometallics, 25, 4179-4182 (2006)
Swayamjeet Satapathy et al.
Clinical nuclear medicine, 45(9), e393-e399 (2020-07-01)
Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options. Peptide receptor radionuclide therapy (PRRT), being specific in targeting the somatostatin receptors, is a promising and viable option in this setting. In this study, we intended to
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 450960-5G | 04061838140135 |
| 450960-1G | 04061838140128 |